双特异性抗体靶向 BCMA、GPRC5D 和 FcRH5 治疗多发性骨髓瘤：2023 年 ASCO 年会最新进展。
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
机构信息
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, Henan, China.
出版信息
J Hematol Oncol. 2023 Aug 3;16(1):92. doi: 10.1186/s13045-023-01489-3.
Abstract
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.
摘要
几种针对 BCMA、GPRC5D 和 FcRH5 的双特异性抗体（bsAbs）正在进行临床试验，用于治疗预处理过的多发性骨髓瘤（MM）患者。Tecelista 单抗于 2022 年被批准用于治疗复发/难治性 MM，而 Elranatamab、Linvoseltamab、F182112、Talquetamab 和 Cevostamab 目前正在进行临床试验。本研究总结了 2023 年 ASCO 年会上关于 bsAbs 治疗 MM 的几项最新报告。
相似文献
1
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.双特异性抗体靶向 BCMA、GPRC5D 和 FcRH5 治疗多发性骨髓瘤：2023 年 ASCO 年会最新进展。
J Hematol Oncol. 2023 Aug 3;16(1):92. doi: 10.1186/s13045-023-01489-3.
2
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.新型获批及即将面世的用于治疗复发/难治性多发性骨髓瘤的靶向 T 细胞的双特异性抗体。
J Oncol Pharm Pract. 2023 Apr;29(3):722-726. doi: 10.1177/10781552231154809. Epub 2023 Feb 12.
3
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.多发性骨髓瘤中的双特异性单克隆抗体：ASH 2022 年会数据：播客节目。
Adv Ther. 2023 Aug;40(8):3291-3303. doi: 10.1007/s12325-023-02551-9. Epub 2023 Jun 16.
4
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.BCMA 或 GPRC5D 靶向的双特异性抗体在多发性骨髓瘤中的疗效、安全性和耐药机制。
Blood. 2024 Mar 28;143(13):1211-1217. doi: 10.1182/blood.2023022499.
5
[Development and prospects of bispecific antibodies for multiple myeloma].[双特异性抗体治疗多发性骨髓瘤的研究进展与展望]
Rinsho Ketsueki. 2024;65(9):1049-1057. doi: 10.11406/rinketsu.65.1049.
6
Targeting GPRC5D in multiple myeloma.靶向多发性骨髓瘤中的 GPRC5D。
Expert Rev Anticancer Ther. 2024 May;24(5):229-238. doi: 10.1080/14737140.2024.2343114. Epub 2024 Apr 16.
7
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.双特异性抗体作为单药或联合治疗血液系统恶性肿瘤：EHA 2023 年年会的最新更新。
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1193-1195. doi: 10.1080/14712598.2023.2273276. Epub 2023 Dec 28.
8
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.多发性骨髓瘤中针对 BCMA、GPRC5D 和 FcRH5 的双特异性抗体相关毒性的管理。
Curr Hematol Malig Rep. 2024 Dec;19(6):237-245. doi: 10.1007/s11899-024-00740-z. Epub 2024 Aug 15.
9
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.针对复发或难治性多发性骨髓瘤的 GPRC5D 免疫疗法：2022 年 ASH 年会的最新进展。
J Hematol Oncol. 2023 Jun 5;16(1):60. doi: 10.1186/s13045-023-01461-1.
10
[Bispecific antibodies in multiple myeloma].[多发性骨髓瘤中的双特异性抗体]
Bull Cancer. 2021 Oct;108(10S):S205-S212. doi: 10.1016/j.bulcan.2021.10.003.
引用本文的文献
1
Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials.双特异性抗体治疗复发/难治性多发性骨髓瘤的安全性和有效性：一项基于临床试验比例的系统评价和荟萃分析
Cancers (Basel). 2025 Aug 22;17(17):2727. doi: 10.3390/cancers17172727.
2
Targets for CAR Therapy in Multiple Myeloma.多发性骨髓瘤中CAR疗法的靶点
Int J Mol Sci. 2025 Jun 24;26(13):6051. doi: 10.3390/ijms26136051.
3
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting.多发性骨髓瘤的新兴治疗药物：2024年美国血液学会年会亮点
Biomark Res. 2025 Jul 1;13(1):90. doi: 10.1186/s40364-025-00803-0.
4
Construction and characterization of chimeric FcγR T cells for universal T cell therapy.用于通用型T细胞疗法的嵌合FcγR T细胞的构建与表征
Exp Hematol Oncol. 2025 Jan 15;14(1):6. doi: 10.1186/s40164-025-00595-x.
5
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds.双特异性抗体的应用进展：收获早期播种的成果并播下新的种子
BioDrugs. 2025 Jan;39(1):75-102. doi: 10.1007/s40259-024-00691-0. Epub 2024 Dec 13.
6
Are we there yet? CAR-T therapy in multiple myeloma.我们到了吗？嵌合抗原受体T细胞（CAR-T）疗法在多发性骨髓瘤中的应用
Br J Haematol. 2024 Dec;205(6):2175-2189. doi: 10.1111/bjh.19896. Epub 2024 Nov 19.
7
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.过继性细胞免疫疗法的进展及多发性骨髓瘤的治疗突破。
Exp Hematol Oncol. 2024 Oct 28;13(1):105. doi: 10.1186/s40164-024-00576-6.
8
Targeting GPRC5D for multiple myeloma therapy.针对多发性骨髓瘤的治疗靶点 GPRC5D。
J Hematol Oncol. 2024 Sep 28;17(1):88. doi: 10.1186/s13045-024-01611-z.
9
Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review.靶向B细胞成熟抗原用于复发/难治性多发性骨髓瘤患者的治疗与监测：综述
Ther Adv Hematol. 2024 Sep 14;15:20406207241275797. doi: 10.1177/20406207241275797. eCollection 2024.
10
Updates on CAR T cell therapy in multiple myeloma.多发性骨髓瘤中嵌合抗原受体T细胞疗法的进展
Biomark Res. 2024 Sep 12;12(1):102. doi: 10.1186/s40364-024-00634-5.
本文引用的文献
1
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.针对复发或难治性多发性骨髓瘤的 GPRC5D 免疫疗法：2022 年 ASH 年会的最新进展。
J Hematol Oncol. 2023 Jun 5;16(1):60. doi: 10.1186/s13045-023-01461-1.
Zotero 插件